Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Beta Bionics (BBNX) Research & Development (2024 - 2026)

Beta Bionics' Research & Development history spans 3 years, with the latest figure at $10.4 million for Q1 2026.

  • On a quarterly basis, Research & Development rose 36.44% to $10.4 million in Q1 2026 year-over-year; TTM through Mar 2026 was $37.6 million, a 32.73% increase, with the full-year FY2025 number at $34.8 million, up 32.86% from a year prior.
  • Research & Development hit $10.4 million in Q1 2026 for Beta Bionics, up from $10.1 million in the prior quarter.
  • Over the last five years, Research & Development for BBNX hit a ceiling of $10.4 million in Q1 2026 and a floor of $5.1 million in Q3 2024.
  • Historically, Research & Development has averaged $7.9 million across 3 years, with a median of $8.2 million in 2025.
  • The widest YoY moves for Research & Development: up 59.4% in 2025, down 9.95% in 2025.
  • Tracing BBNX's Research & Development over 3 years: stood at $9.2 million in 2024, then rose by 9.95% to $10.1 million in 2025, then rose by 2.22% to $10.4 million in 2026.
  • Business Quant data shows Research & Development for BBNX at $10.4 million in Q1 2026, $10.1 million in Q4 2025, and $8.2 million in Q3 2025.